Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02196506
Previous Study | Return to List | Next Study

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02196506
Recruitment Status : Completed
First Posted : July 22, 2014
Results First Posted : August 21, 2018
Last Update Posted : August 21, 2018
Sponsor:
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:
The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress

Condition or disease Intervention/treatment Phase
Depressive Disorder Depression Depressive Disorder, Major Mood Disorders Mental Disorders Drug: Placebo + ADT Drug: Brexpiprazole +ADT Phase 3

Detailed Description:
The introduction of atypical antipsychotics has created a renewed interest in adjunctive therapy for MDD, particularly for treatment-resistant MDD. Several atypical antipsychotics have been shown to enhance the response to ADT. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the safety and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy to an assigned open-label ADT in depressed subjects with and without anxious distress.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 837 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Study Start Date : July 2014
Actual Primary Completion Date : April 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: Brexpiprazole + ADT
Brexpiprazole + ADT
Drug: Brexpiprazole +ADT
Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)

Placebo Comparator: Placebo + ADT
Placebo + ADT
Drug: Placebo + ADT
Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)




Primary Outcome Measures :
  1. Change in the Montgomery-Asberg Depression [ Time Frame: From baseline (end of Phase A [Week 8]) to week 14 ]
    To assess the change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score from Baseline (End of Phase A [Week 8]) to Week 14. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The rater decided whether the rating lied on predefined scale steps (0, 2, 4, 6) or between them (1, 3, 5). The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.


Secondary Outcome Measures :
  1. Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment [ Time Frame: From baseline (end of Phase A [Week 8]) to week 14 ]
    To assess the change in the Sheehan Disability Scale (SDS) Score (the mean of 3 individual item scores) from Baseline (End of Phase A [Week 8]) to Week 14 (End of Phase B). SDS was a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life, and family life/home responsibility. Each item was scored using a scale of 0 to 10 (a higher score indicates symptoms have disrupted work, social life, and family life/home responsibility extremely). The maximum total score was 30; 0 = not at all, to 30 = extremely.

  2. Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score [ Time Frame: From baseline (end of Phase A [Week 8]) to week 14 ]
    To assess the change from end of Phase A (Week 8 visit) to end of Phase B (Week 14 visit) in MADRS Total Score for the subpopulation with < 25% improvement from baseline of Phase A (Week 0) to end of Phase A (Week 8) in MADRS Total Score. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

  3. Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). [ Time Frame: From baseline (end of Phase A [Week 8]) to week 14 ]
    To assess the change from end of Phase A (Week 8) to end of Phase B (Week 14) in MADRS Total Score for the subpopulations with anxious distress as specified in DSM-V. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and Female subjects between 18-65 years of age, with diagnosis of major depressive disorder with or without anxious distress
  • Current depressive episode must be at least 8 weeks in duration

Exclusion Criteria:

  • Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome
  • Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode
  • Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02196506


Locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, California
Beverly Hills, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Florida
Hialeah, Florida, United States
Orlando, Florida, United States
United States, Georgia
Alpharetta, Georgia, United States
Smyrna, Georgia, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Rochester Hills, Michigan, United States
United States, New Jersey
Cherry Hill, New Jersey, United States
United States, New York
Jamaica, New York, United States
New York, New York, United States
Staten Island, New York, United States
United States, North Carolina
Raleigh, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Oklahoma
Edmond, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
Salem, Oregon, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Rhode Island
Lincoln, Rhode Island, United States
United States, South Carolina
Columbia, South Carolina, United States
United States, Tennessee
Memphis, Tennessee, United States
United States, Texas
Wichita Falls, Texas, United States
United States, Utah
Murray, Utah, United States
United States, Vermont
Woodstock, Vermont, United States
United States, Virginia
Charlottesville, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Seattle, Washington, United States
Spokane, Washington, United States
Germany
Achim, Germany
Berlin, Germany
Dusseldorf, Germany
Frankfurt, Germany
Freiburg, Germany
Oranienburg, Germany
Stralsund, Germany
Wurzburg, Germany
Hungary
Budapest, Hungary
Gyor, Hungary
Poland
Gdansk, Poland
Lubin, Poland
Sosnowiec, Poland
Warszawa, Poland
Slovakia
Bratislava, Slovakia
Kosice-Barca, Slovakia
Liptovsky Mikulas, Slovakia
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
H. Lundbeck A/S
Investigators
Layout table for investigator information
Study Director: Claudette Brewer Otsuka Pharmaceutical Development & Commercialization, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT02196506    
Other Study ID Numbers: 331-13-214
First Posted: July 22, 2014    Key Record Dates
Results First Posted: August 21, 2018
Last Update Posted: August 21, 2018
Last Verified: August 2018
Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
OPC-34712
brexpiprazole
Major Depressive Disorder
Adjunctive Treatment
Anxious Distress
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Depression
Depressive Disorder
Depressive Disorder, Major
Mental Disorders
Mood Disorders
Pathologic Processes
Behavioral Symptoms
Brexpiprazole
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents